Alvaro Zamora, MD
Vascular Surgery · Naples, FLNPI 1194056010
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.8%), food and beverage and other — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 51.9% of the total. Reporting peaked in 2023 at $10,462 and has fallen 91.3% since, to $911 in 2025.
Across 220 payments — averaging $73.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Endologix LLC$3K
- Cashflow Solutions, LLC$2K
- W. L. Gore & Associates, Inc.$1K
- Johnson & Johnson$443
- Cvrx, Inc.$308
- plus $1K from 20 others
Across 8 payments — averaging $2355.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$19K
What the payments were for
- Travel & lodging$7,72248%
- Food & beverage$6,73342%
- Other$1,71411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 76 | $8,386 |
| Endologix LLC | 22 | $2,516 |
| Cashflow Solutions, LLC | 2 | $1,727 |
| W. L. Gore & Associates, Inc. | 17 | $1,310 |
| Johnson & Johnson | 40 | $443 |
| Cvrx, Inc. | 11 | $308 |
| Cook Medical LLC | 11 | $279 |
| Silk Road Medical, Inc. | 9 | $231 |
| Bolton Medical Inc | 3 | $214 |
| Boston Scientific | 4 | $115 |
| Novo Nordisk | 1 | $113 |
| Lemaitre Vascular, Inc. | 2 | $77 |
| Penumbra, Inc. | 4 | $76 |
| Shockwave Medical, Inc | 1 | $49 |
| Smith+Nephew | 2 | $41 |
| Angiodynamics, Inc. | 2 | $37 |
| Inari Medical, Inc. | 2 | $33 |
| Pfizer | 2 | $30 |
| Baxter Healthcare | 1 | $30 |
| Stryker | 1 | $27 |
| Cardiva Medical, Inc. | 1 | $27 |
| Artivion, Inc. | 2 | $25 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Biocompatibles, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Terumo Medical Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IN.PACT Admiral$6,235
- Lympha Press Optimal Plus(US) BT$1,714
- PCD-51 731A (US) - White$1,714
- PCD-52 737A (US) White$1,714
- TurboHawk$962
- Ovation$750
- Alto Abdominal Stent Graft System$735
- AFX2 Bifurcated Endograft System$735
- AFX$524
- GORE TAG Thoracic Endoprosthesis$437
- Ovation iX Iliac Stent Graft$429
- Abre$161
- EXCLUDER Iliac Branch Endoprosthesis$139
- GORE TAG Thoracic Branch Endoprosthesis$138
- Barostim Neo System$136
- VIABAHN VBX Balloon Expandable Endoprosthesis$127
- Relay Grafts$121
How this compares
$16,170 in reported general payments places this provider in the 75th percentile of 385 vascular surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $64,608 |
| XareltoRivaroxaban | 47 | $44,115 |
| ClopidogrelClopidogrel Bisulfate | 118 | $928 |
| Cilostazol | 51 | $801 |
| Atorvastatin Calcium | 20 | $377 |
| Oxycodone Hcl | 66 | $196 |
| Tramadol Hcl | 35 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $64,60875 claims |
| Johnson & JohnsonXarelto | $443 | $44,11547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 385 vascular surgery providers in Florida.
Other vascular surgery in Naples
- Rajesh MalikNaples$237K
- Hiranya RajasingheNaples$37K
- Samuel TapperStuart$1.3M
- Mariano ArosemenaBradenton$472K
- Manuel Perez IzquierdoOrlando$302K
- Erin MooreJacksonville$300K
- Charles BaileyTampa$162K
- Joseph WasselleMelbourne$161K
- Joseph RicottaDelray Beach$156K
- Murray ShamesTampa$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.